Cellular and pathological functions of tau
Top Cited Papers
- 16 July 2024
- journal article
- review article
- Published by Springer Nature in Nature Reviews Molecular Cell Biology
- Vol. 25 (11) , 845-864
Abstract
Tau protein is involved in various cellular processes, including having a canonical role in binding and stabilization of microtubules in neurons. Tauopathies are neurodegenerative diseases marked by the abnormal accumulation of tau protein aggregates in neurons, as seen, for example, in conditions such as frontotemporal dementia and Alzheimer disease. Mutations in tau coding regions or that disrupt tau mRNA splicing, tau post-translational modifications and cellular stress factors (such as oxidative stress and inflammation) increase the tendency of tau to aggregate and interfere with its clearance. Pathological tau is strongly implicated in the progression of neurodegenerative diseases, and the propagation of tau aggregates is associated with disease severity. Recent technological advancements, including cryo-electron microscopy and disease models derived from human induced pluripotent stem cells, have increased our understanding of tau-related pathology in neurodegenerative conditions. Substantial progress has been made in deciphering tau aggregate structures and the molecular mechanisms that underlie protein aggregation and toxicity. In this Review, we discuss recent insights into the diverse cellular functions of tau and the pathology of tau inclusions and explore the potential for therapeutic interventions.Keywords
This publication has 374 references indexed in Scilit:
- PRX005, a novel anti‐MTBR tau monoclonal antibody: results from a first‐in‐human double‐blind, placebo‐controlled, single ascending dose phase 1 studyAlzheimer's & Dementia, 2023
- E2814: an anti‐tau therapy engages its CNS target and affects the downstream tangle‐specific biomarker MTBR‐tau243 in Dominantly Inherited Alzheimer’s DiseaseAlzheimer's & Dementia, 2023
- APNmAb005, an anti‐tau antibody targeting synaptic tau oligomers, in Phase 1 for treatment of Alzheimer’s Disease and primary tauopathiesAlzheimer's & Dementia, 2023
- Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer DiseaseJAMA Neurology, 2023
- APOE Christchurch‐mimetic therapeutic antibody reduces APOE‐mediated toxicity and tau phosphorylationAlzheimer's & Dementia, 2023
- The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive declineAlzheimer's & Dementia, 2023
- Mitophagy alterations in Alzheimer's disease are associated with granulovacuolar degeneration and early tau pathologyAlzheimer's & Dementia, 2020
- Deep clinical and neuropathological phenotyping of Pick diseaseAnnals of Neurology, 2015
- Tau reduction prevents disease in a mouse model of Dravet syndromeAnnals of Neurology, 2014
- Frequency of Tau Gene Mutations in Familial and Sporadic Cases of Non-Alzheimer DementiaArchives of Neurology, 2001